Evidence map›Paper›PMID 41844278›Full record

ArticleLife science alliance2026

TBXA2R activates ERMs to drive motility, invasion, and metastatic colonization of TNBC cells.

Kévin Leguay, Omaima Naffati, Camila Lie Kiyan, Yu Yan He, Mireille Hogue, Chloé Tesnière, Melania Gombos, Hellen Kuasne, Louis Gaboury, Christian Le Gouill and 3 more

Abstract read
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kévin LeguayInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada leguay.kevin@gmail.com.ORCID 0000-0002-5691-4157
Omaima NaffatiInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Camila Lie KiyanInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Yu Yan HeInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Mireille HogueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Chloé TesnièreInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Melania GombosInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Hellen KuasneRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada.
Louis GabouryInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Christian Le GouillInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.
Sylvain MelocheInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada.ORCID 0000-0002-6201-7786
Michel BouvierInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada michel.bouvier@umontreal.ca.ORCID 0000-0003-1128-0100
Sébastien CarrénoInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Canada sebastien.carreno@umontreal.ca.ORCID 0000-0002-5839-2102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell migration and invasion are critical for cancer cell metastasis, relying on the ability of cells to adapt their morphology. Proteins of the ezrin, radixin, and moesin (ERM) family are key regulators of cell morphogenesis and essential determinants of cancer cell metastasis. However, the mechanisms by which ERMs are activated in metastatic cells remain poorly understood. We identified the thromboxane A2 receptor (TBXA2R), a G protein-coupled receptor overexpressed in multiple cancers, as a critical activator of ERMs, enhancing the motility and invasion of triple-negative breast cancer cells. We found that TBXA2R activates ERMs by engaging the Gα

Indexed as

Cytoskeletal ProteinsMembrane ProteinsMicrofilament ProteinsReceptors, Thromboxane A2, Prostaglandin H2Triple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementEzrinFemaleHumansMiceNeoplasm InvasivenessNeoplasm MetastasisSignal TransductionCytoskeletal ProteinsEzrinMembrane ProteinsMicrofilament ProteinsmoesinradixinReceptors, Thromboxane A2, Prostaglandin H2

Identifiers

PMID41844278
PMCPMC12996826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.